UNSPSC 51313004: Talastine hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H21N3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SBH6TU2VU4, chemically known as 2-(2-(dimethylamino)ethyl)-4-(phenylmethyl)-1(2h)-phthalazinone hydrochloride, but more generally known as talastine hydrochloride, which bears US NIH Compound Identifier 167517. European Medicines Agency schedules talastine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10801MIG.

Most nations, for tariff purposes, schedule talastine hydrochloride under HS 29339990. Talastine hydrochloride bears US NLM identifiers UMLS ID C0121937 and NCI Concept Code C95238. SMILES: CN(C)CCN1C(=O)C2CCCCC2C(N1)CC3CCCCC3.CL.

UNSPSC 51313004 Talastine hydrochloride is a Commodity code that does not reflect the pharmaceutical procurement activity appearing in the recent state and local opportunities associated with it. The named opportunities—Seminole County's procurement of naloxone and drug deactivation systems, Texas HHS's request for information on direct-to-manufacturer prescription programs, and MMCAP's multi-state RFP for generic pharmaceuticals and OTC products—involve naloxone, generic multi-source pharmaceuticals, and OTC products rather than talastine hydrochloride specifically. The opportunities reveal that state and local governments are buying pharmaceutical products, drug deactivation equipment, and pharmacy benefit management services through county health departments, state health agencies, and multi-state cooperative purchasing vehicles. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances administered by state procurement offices (Minnesota Department of Administration on behalf of MMCAP members across multiple states including Oregon).

The geographic spread spans Florida, Texas, Minnesota, and Oregon based on recent solicitations. Representative recent opportunities include Seminole County's IFB60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (note: the due date appears inconsistent with the posting date); Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, with an April 3, 2026 response deadline, exploring direct-to-manufacturer prescription program capabilities; and MMCAP's RFP S1070000015802, posted January 20, 2026, with a March 26, 2026 proposal deadline, establishing multi-state contracts for generic pharmaceuticals and OTC products through authorized wholesalers. The code shows limited relevant recent activity aligned with its nominal scope; state and local pharmaceutical procurement activity appears primarily under broader generic and OTC product categories rather than under this specific commodity designation.